This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Vinconate
A vinca alkaloid derivative related to vinpocetine that enhances cerebral blood flow through phosphodiesterase inhibition and calcium channel blocking, marketed in Japan for cerebrovascular disorders.
Benefits
What is Vinconate?
Vinconate (ethyl apovincaminate analogue) is a semi-synthetic vinca alkaloid derivative structurally and pharmacologically related to vinpocetine, both being derived from the periwinkle plant (Vinca minor) alkaloid vincamine. Marketed in Japan under various brand names for the treatment of cerebrovascular disorders and associated cognitive impairment, Vinconate enhances cerebral blood flow, improves brain energy metabolism, and provides neuroprotective effects. Like its better-known relative vinpocetine, Vinconate acts primarily through phosphodiesterase type 1 (PDE1) inhibition and voltage-gated calcium channel blockade, but it has a distinct pharmacokinetic profile and receptor binding characteristics that differentiate it clinically. Japanese clinical studies have demonstrated that Vinconate improves symptoms of cerebral insufficiency including dizziness, headache, memory impairment, and reduced cognitive performance in elderly patients.
The cerebrovascular effects of Vinconate are mediated through multiple complementary mechanisms. PDE1 inhibition leads to increased intracellular cGMP and cAMP levels in vascular smooth muscle, causing vasodilation and improved blood flow through cerebral arterioles. Calcium channel blockade further contributes to vasodilation and provides neuroprotection by preventing excessive calcium influx into neurons during ischaemic events. Research published in Japanese pharmacological journals, including work by Ishihara et al. (1989) in the Journal of Cerebral Blood Flow and Metabolism, demonstrated that Vinconate selectively increases cerebral blood flow without significantly affecting systemic blood pressure - a property known as cerebral vascular selectivity. Additionally, Vinconate has been shown to improve glucose and oxygen utilisation in brain tissue, enhance red blood cell flexibility (improving microcirculation), and inhibit platelet aggregation. Although well-established in Japanese clinical practice since the 1980s, Vinconate remains largely unknown in Western medicine, where vinpocetine has dominated the vinca alkaloid nootropic market.
- Phosphodiesterase type 1 inhibition: Inhibits PDE1 in cerebral vascular smooth muscle, elevating intracellular cGMP and cAMP levels, leading to smooth muscle relaxation and cerebral vasodilation with selective enhancement of brain blood flow
- Calcium channel blockade: Blocks voltage-gated calcium channels in both vascular smooth muscle and neurons, contributing to vasodilation and providing neuroprotection against calcium-mediated excitotoxic damage
- Cerebral glucose and oxygen utilisation: Enhances the efficiency of aerobic glucose metabolism in neurons and glial cells, improving ATP production and supporting the energy demands of cognitive processing
- Red blood cell rheology improvement: Increases red blood cell deformability, allowing them to pass more easily through narrow cerebral capillaries and improving oxygen delivery to brain tissue at the microcirculation level
- Antiplatelet activity: Inhibits platelet aggregation through PDE inhibition-mediated increases in platelet cAMP, reducing the risk of microthrombosis in cerebral vasculature and improving microcirculatory flow
- Standard clinical dose: 15-30 mg taken two to three times daily (total daily dose of 30-90 mg) as used in Japanese clinical practice
- Starting dose: 15 mg twice daily, with gradual titration based on clinical response and tolerability
- Duration of treatment: Treatment courses of 8-12 weeks are typical in clinical trials, with many patients receiving long-term maintenance therapy for chronic cerebrovascular conditions
- Administration: Oral tablets taken after meals to improve absorption and reduce gastrointestinal side effects
- Availability: Available primarily in Japan through prescription; not approved by the FDA or EMA and generally unavailable through Western supplement or research chemical channels
- Generally well-tolerated: Japanese post-marketing surveillance has shown a favourable safety profile, with adverse effects typically being mild and transient
- Gastrointestinal effects: The most commonly reported side effects include nausea, abdominal discomfort, and loss of appetite, usually mild and self-limiting
- Hypotensive effects: Although cerebrovascular selectivity minimises systemic blood pressure effects, some patients may experience mild dizziness or lightheadedness, particularly when rising from a seated or lying position
- Antiplatelet interaction: Due to its antiplatelet activity, caution is warranted in patients taking anticoagulants (warfarin, heparin) or other antiplatelet agents (aspirin, clopidogrel) due to increased bleeding risk
- Hepatic metabolism: Metabolised primarily by the liver; patients with significant hepatic impairment may require dose adjustment or more careful monitoring
Natural Sources & Forms
- Ishihara et al. (1989): Study on Vinconate's effects on cerebral blood flow and metabolism published in the Journal of Cerebral Blood Flow and Metabolism, demonstrating cerebrovascular selectivity
- Japanese pharmaceutical product information: Official prescribing information for Vinconate tablets as approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
- Vinca alkaloid review: Vas and Bhatt (2008) - comprehensive review of vinca alkaloid derivatives including vincamine, vinpocetine, and Vinconate for cerebrovascular and cognitive applications
- PDE inhibitor pharmacology: Bender and Bhatt (2006) - "Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use" in Pharmacological Reviews, covering PDE1 inhibitors including vinca alkaloid derivatives
- Cerebrovascular pharmacotherapy: Hagiwara et al. (1984) - "Pharmacological profile of Vinconate" in Japanese Journal of Pharmacology, providing comprehensive preclinical characterisation
Frequently Asked Questions
A vinca alkaloid derivative related to vinpocetine that enhances cerebral blood flow through phosphodiesterase inhibition and calcium channel blocking, marketed in Japan for cerebrovascular disorders.
The key benefits of Vinconate include: Cognitive Enhancement, Energy, Focus, Longevity, Memory, Mood.
Phosphodiesterase type 1 inhibition: Inhibits PDE1 in cerebral vascular smooth muscle, elevating intracellular cGMP and cAMP levels, leading to smooth muscle relaxation and cerebral vasodilation with selective enhancement of brain blood flow Calcium channel blockade: Blocks voltage-gated calcium channels in both vascular smooth muscle and neurons, contributing to vasodilation and providing neuroprotection against calcium-mediated excitotoxic damage Cerebral glucose and oxygen utilisation: Enhances the efficiency of aerobic glucose metabolism in neurons and glial cells, improving ATP production and supporting the energy demands of cognitive processing Red blood cell rheology improvement: Increases red blood cell deformability, allowing them to pass more easily through narrow cerebral capillaries and improving oxygen delivery to brain tissue at the microcirculation level Antiplatelet activity: Inhibits platelet aggregation through PDE inhibition-mediated increases in platelet cAMP, reducing the risk of microthrombosis in cerebral vasculature and improving microcirculatory flow
Standard clinical dose: 15-30 mg taken two to three times daily (total daily dose of 30-90 mg) as used in Japanese clinical practice Starting dose: 15 mg twice daily, with gradual titration based on clinical response and tolerability Duration of treatment: Treatment courses of 8-12 weeks are typical in clinical trials, with many patients receiving long-term maintenance therapy for chronic cerebrovascular conditions Administration: Oral tablets taken after meals to improve absorption and reduce gastrointestinal side effects Availability: Available primarily in Japan through prescription; not approved by the FDA or EMA and generally unavailable through Western supplement or research chemical channels
Generally well-tolerated: Japanese post-marketing surveillance has shown a favourable safety profile, with adverse effects typically being mild and transient Gastrointestinal effects: The most commonly reported side effects include nausea, abdominal discomfort, and loss of appetite, usually mild and self-limiting Hypotensive effects: Although cerebrovascular selectivity minimises systemic blood pressure effects, some patients may experience mild dizziness or lightheadedness, particularly when rising from a seated or lying position Antiplatelet interaction: Due to its antiplatelet activity, caution is warranted in patients taking anticoagulants (warfarin, heparin) or other antiplatelet agents (aspirin, clopidogrel) due to increased bleeding risk Hepatic metabolism: Metabolised primarily by the liver; patients with significant hepatic impairment may require dose adjustment or more careful monitoring
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!